Shopping Cart
Remove All
Your shopping cart is currently empty
KHK-2866 is a humanized monoclonal antibody targeting Heparin-Binding Epidermal Growth Factor-like Growth Factor (HB-EGF). By binding to HB-EGF, KHK-2866 blocks its interaction with EGFR and HER4 receptors, thereby inhibiting the proliferation and survival of tumor cells. HB-EGF is frequently overexpressed in various solid tumors, making it a key therapeutic target.

| Description | KHK-2866 is a humanized monoclonal antibody targeting Heparin-Binding Epidermal Growth Factor-like Growth Factor (HB-EGF). By binding to HB-EGF, KHK-2866 blocks its interaction with EGFR and HER4 receptors, thereby inhibiting the proliferation and survival of tumor cells. HB-EGF is frequently overexpressed in various solid tumors, making it a key therapeutic target. |
| In vitro | In Lat1-expressing human cancer cell lines, KHK-2866 demonstrated high affinity binding and effectively inhibited amino acid uptake [1]. |
| In vivo | In human tumor xenograft models, systemic administration of KHK-2866 significantly suppressed tumor growth by blocking Lat1-mediated nutrient transport [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | HBEGF |
| Cas No. | 1832713-21-9 |
| Isotype | IgG2SA |
| Storage | store at low temperature | Lyophilized powder: -20~-80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.